The company’s adjusted earnings excluded $900,000 in after-tax charges related to the J&J’s acquisition of Synthes, in-process R&D and an increase in the accrual for litigation expenses.
J&J boosted its earnings guidance for the full year from an adjusted EPS range of $5.40 to $5.47 to a new range of $5.44 to $5.49. The consensus estimate had called for EPS of $5.46 on revenues of $70.81 billion. For the first nine months of the year, the company has posted revenues of $52.96 billion and diluted adjusted EPS of $4.28.
The firm’s CEO said:
Our third-quarter results reflect the solid, demonstrable results in achieving our near-term priorities while also advancing our longer term strategic growth drivers. Our key products and successful new product launches delivered strong growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of new drug applications, and execution of strategic collaborations.
Worldwide consumer sales rose 0.8% year-over-year to $3.61 billion, including a negative currency impact of 1.2%. Pharmaceutical sales rose 9.9% to $7.04 billion. Medical devices and diagnostics sales fell 2% to $6.93 billion. The negative currency exchange impact on total revenues was 1.6% in the quarter.
Although sales totals were higher in each of the company’s segments, year-over-year growth did not match second-quarter growth in any of them. Consumer sales in the second quarter were up 1.1%, drug sales were up 11.7%, and devices and diagnostics sales were up 9.6%. For all the happy talk, this is not a good sign.
Shares are trading about 1% higher in the premarket Tuesday morning, at $91.45 in a 52-week range of $68.51 to $94.42. Thomson Reuters had a consensus analyst price target of around $94.10 before these results were announced.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
